Discovery consists of looking at the same thing as everyone else and thinking something different.
— Albert Szent-Gyorgi, Nobel Laureate and Hungarian biochemist
Cell BT is a different kind of immuno-oncology innovation company. A small company with an academic infrastructure, we’re uniquely positioned to research, test and rapidly advance multiple discoveries at once. Time is of the essence in CAR T science; with shortened innovation cycles, this promising medicine will bring hope to patients sooner.
We look at CAR T therapy for both solid and hematological cancers from a fresh perspective. We ask, “What are the barriers to CAR T-cell success?” —and we uncover ways to solve them.
To accomplish this, we are developing novel platforms and targets for solid tumors, while also improving CAR T efficacy for blood cancers. Among our programs is a universal therapeutic designed to reduce adverse side effects and improve accessibility for all CAR T-cell treatments.
The story of cell therapy is still being written, and Cell BT is working hard to play a leading role in the next chapter.
Because it uses the patient’s own immune cells, it is a true personalized medicine.
These autologous cells form the basis of a living, breathing treatment that can respond to tumor burden by expanding and decreasing as needed.
Autologous CAR T-cells are proven and free from the shortcomings of bi-specific and allogeneic treatments, such as the need for multiple doses, risk of rejection and short half-lives. They involve none of the poisons used in chemotherapy drugs and radiation.
CAR T-cell therapy has changed patient outcomes for blood malignancies in ways that were once inconceivable, and efforts are underway across the globe to bring this success to other tumor classes. Cell BT is pioneering multiple innovations for both solid tumor and hematological cancer therapies.
CAR T-cell therapy has changed patient outcomes for blood malignancies in ways that were once inconceivable, and efforts are underway across the globe to bring this success to other tumor classes. Cell BT is pioneering multiple innovations for both solid and liquid tumor therapies.
While many are discouraged by CART-T’s lack of success treating solid tumors, Cell BT sees a bright light of hope.
Ready for Phase One clinical trial, our lead hematological program is based on a powerful combination of a unique platform and a novel target.
We’re seeing new ways CAR T-cells can engage the patient’s own immune system to synergistically target and destroy tumors.
Cell BT is meeting one of the greatest challenges facing broad CAR T availability: cost.
Cell BT’s Chief Scientific Officer, Alan Epstein, MD, PhD, is a Professor at the Keck School of Medicine at the University of Southern California. Dr. Epstein is internationally recognized for his expertise in the development of monoclonal antibodies and other immuno-oncology treatments.
We believe in leading with science, and Dr. Epstein’s experience and visionary approach put Cell BT in a category of its own.